CJC-1295 (without DAC) vs HMG
Well Studied vs Extensively Studied
monitor Mechanism-based · 51% Both CJC-1295 (without DAC) and HMG can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 (without DAC) HMG
Weight 3,367.97 Da —
Half-life 30 minutes - 2 hours ~32 hours (FSH component: 39-54 hours)
Chain 30 amino acids —
Type GHRH analog Gonadotropin mixture
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
HMG
01 FDA-approved for fertility treatment
02 Stimulates ovarian follicle development
03 Contains both FSH and LH naturally
04 Promotes spermatogenesis in men
05 Cost-effective alternative to recombinant FSH
06 LH activity may improve fertilization rates
07 Long clinical track record
08 Lower OHSS incidence with HP-hMG
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
HMG
75-150 IU for ovulation induction; 150-300 IU for IVF / Daily during stimulation phase (7-12 days)
Ovulation induction 75-150 IU Daily
IVF stimulation 150-300 IU Daily for 7-12 days
Male fertility 75-150 IU 2-3x weekly
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
HMG
Injection site reactions
Abdominal discomfort
Ovarian enlargement
Mood changes
Headache
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Primary ovarian failure
Uncontrolled thyroid or adrenal dysfunction
Sex hormone-dependent tumors
Abnormal uterine bleeding of unknown cause
Ovarian cysts (not due to PCOS)
Pregnancy
Research Evidence
CJC-1295 (without DAC) HMG
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest November 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.